Cognitive improvement by daily intake of coffee cherry pulp extract from Coffea canephora var. Robusta in a Japanese population: A randomized, placebo-controlled, double-blind, parallel-group comparison trial.

Complement Ther MedJun 16, 2026 (epub)
Clinical ResearchNeurologyPsychiatry

Shingo Ariki, Rikito Mitsuzane, Shiori Morimoto et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized, placebo-controlled trial investigated the effects of coffee cherry pulp extract (CCPER) on cognitive function in 66 Japanese adults aged ≥40 with suspected mild cognitive impairment. After 12 weeks, the high-dose CCPER group showed a significant improvement in memory scores compared to placebo, with a difference of 12.1 (95% CI: 0.7-23.5, P=0.038).

Key findings

  • The high-dose CCPER group had a significant memory score improvement of 12.1 compared to placebo.
  • No significant cognitive improvement was observed in the low-dose CCPER group.
  • CCPER and PCs significantly promoted neurite extension in PC12 cells compared to control.

Why it matters

Cognitive decline is a significant concern in aging populations. This study suggests that coffee cherry pulp extract may offer a novel dietary approach to enhance cognitive function, particularly in individuals with mild cognitive impairment.

Source

PubMed · PMID 42302880

Published in Complement Ther Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.